Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis

Maurizio Cutolo, Marianna Meroni Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy Abstract: Immune/inflammatory cells act in rheumatoid arthritis (RA)-affected patients by synthesizing several inflammatory medi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cutolo M, Meroni M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/5d3a696edf404f14beeee91665f68c15
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5d3a696edf404f14beeee91665f68c15
record_format	dspace
spelling	oai:doaj.org-article:5d3a696edf404f14beeee91665f68c152021-12-02T04:11:59ZClinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis1178-7031https://doaj.org/article/5d3a696edf404f14beeee91665f68c152013-11-01T00:00:00Zhttp://www.dovepress.com/clinical-utility-of-the-oral-jak-inhibitor-tofacitinib-in-the-treatmen-a14989https://doaj.org/toc/1178-7031Maurizio Cutolo, Marianna Meroni Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy Abstract: Immune/inflammatory cells act in rheumatoid arthritis (RA)-affected patients by synthesizing several inflammatory mediators, including cytokines that initiate intracellular signaling. Recently, small molecule inhibitors of transduction and transcription signals that influence the intracellular pathways (such as the Janus kinase [JAK] family of tyrosine kinases) have been tested for RA treatment. Four members of the JAK family are known: JAK1, JAK2, JAK3, and TyK2. JAK1/JAK3 constitutively binds to the cytoplasmic portion of the cytokine receptor – the common gamma chain – that represents a common subunit of several cytokines involved in T-cell and natural killer cell development, as well as in B-cell activation. Tofacitinib is an oral JAK inhibitor that is now available and effective in RA treatment, as shown in multiple Phase II and Phase III clinical trials. However, long-term safety data and comparisons with other disease-modifying antirheumatic drugs and small molecule inhibitors are necessary to better determine the role of tofacitinib in RA. Keywords: Janus kinase inhibitors, tofacitinib, rheumatoid arthritis, kinases, small molecules inhibitors, intracellular signalingCutolo MMeroni MDove Medical PressarticlePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol 2013, Iss default, Pp 129-137 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Cutolo M Meroni M Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
description	Maurizio Cutolo, Marianna Meroni Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy Abstract: Immune/inflammatory cells act in rheumatoid arthritis (RA)-affected patients by synthesizing several inflammatory mediators, including cytokines that initiate intracellular signaling. Recently, small molecule inhibitors of transduction and transcription signals that influence the intracellular pathways (such as the Janus kinase [JAK] family of tyrosine kinases) have been tested for RA treatment. Four members of the JAK family are known: JAK1, JAK2, JAK3, and TyK2. JAK1/JAK3 constitutively binds to the cytoplasmic portion of the cytokine receptor – the common gamma chain – that represents a common subunit of several cytokines involved in T-cell and natural killer cell development, as well as in B-cell activation. Tofacitinib is an oral JAK inhibitor that is now available and effective in RA treatment, as shown in multiple Phase II and Phase III clinical trials. However, long-term safety data and comparisons with other disease-modifying antirheumatic drugs and small molecule inhibitors are necessary to better determine the role of tofacitinib in RA. Keywords: Janus kinase inhibitors, tofacitinib, rheumatoid arthritis, kinases, small molecules inhibitors, intracellular signaling
format	article
author	Cutolo M Meroni M
author_facet	Cutolo M Meroni M
author_sort	Cutolo M
title	Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
title_short	Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
title_full	Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
title_fullStr	Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
title_full_unstemmed	Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
title_sort	clinical utility of the oral jak inhibitor tofacitinib in the treatment of rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/5d3a696edf404f14beeee91665f68c15
work_keys_str_mv	AT cutolom clinicalutilityoftheoraljakinhibitortofacitinibinthetreatmentofrheumatoidarthritis AT meronim clinicalutilityoftheoraljakinhibitortofacitinibinthetreatmentofrheumatoidarthritis
_version_	1718401369534103552

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis

Ejemplares similares